Baxter International, Inc. has signed an agreement with Kaketsuken, the Chemo-Sero-Therapeutic Research Institute based in Kumamoto Japan, for the worldwide rights to develop, manufacture and market the recombinant protein ADAMTS13 for the treatment of thrombotic thrombocytopenic purpura (TTP) and related disorders.     ADAMTS13 is a bio-engineered version of a naturally occurring enzyme that plays a critical role in blood coagulation. TTP is a severe, often life-threatening condition marked...